CATO SMS has more than 30 years of extensive experience in neurology, involving collaborations with numerous sponsors, including treatment of more than 20 indications. To date, we have participated in more than 150 clinical development projects in central nervous system indications at sites throughout the world.

We also interact extensively with regulatory agencies such as the FDA, including the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), the European Medicines Agency (EMA), Health Canada and the Canadian Health Products and Food Branch Inspectorate (HPFBI). Ongoing contact with these regulatory groups keeps us up to date on current regulatory solutions.

Our experience and expertise includes:

  • Movement disorders
  • Neurodegenerative diseases
  • Neurovascular diseases
  • Demyelinating disorders
  • Seizure disorders